Product Description
Involucrin Antibody [SPM259] | 34-123 | ProSci
Host: Mouse
Reactivity: Human, Gorilla, Owl Monkey, Pig, Dog
Homology: N/A
Immunogen: Purified involucrin from human keratinocytes was used as the immunogen for this Involucrin antibody. Its epitope maps between amino acids 421-568 of human involucrin.
Research Area: Cancer, Signal Transduction
Tested Application: Flow, IF, IHC
Application: Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
Immunofluorescence: 1-2 ug/ml
Immunohistochemistry (FFPE) : 0.1-0.2 ug/ml for 30 min at RT (1)
Prediluted format : incubate for 30 min at RT (2)
The optimal dilution of the Involucrin antibody for each application should be determined by the researcher.
1. Staining of formalin-fixed tissues is enhanced by digestion with Trypsin or Protease XXV at 1mg/ml PBS for 5 min at 37oC. Enzyme digestion is better than citrate buffer based epitope unmasking.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required) , drip mAb solution onto the tissue section and incubate at RT for 30 min.
Specificiy: Does not react with Mouse
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: Protein G affinity chromatography
Clonality: Monoclonal
Clone: SPM259
Isotype: IgG1, kappa
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.
Alternate Name: IVL,
User Note: Optimal dilutions for each application to be determined by the researcher
BACKGROUND: Involucrin is expressed in a range of stratified squamous epithelia, including the cornea, which lacks a distinct cornified layer. In normal epidermis, it is first expressed in the upper spinous layers, and in keratinocyte cultures, all cells that have left the basal layer express it. Involucrin expression is altered in pathological conditions: in psoriasis and other benign epidermal hyperplasias, involucrin expression begins closer to the basal layer than normal; expression is abnormal in squamous cell carcinomas and premalignant lesions, and is reduced in severe dysplasias of the larynx and cervix.